David Loomis Sells 1,108 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,108 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $12.16, for a total transaction of $13,473.28. Following the completion of the transaction, the chief accounting officer owned 29,692 shares of the company’s stock, valued at $361,054.72. This trade represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Arvinas Price Performance

Shares of NASDAQ:ARVN opened at $13.38 on Friday. The stock has a market cap of $855.78 million, a price-to-earnings ratio of -10.45 and a beta of 1.88. Arvinas, Inc. has a 12 month low of $5.90 and a 12 month high of $18.93. The stock’s 50 day moving average price is $12.45 and its 200 day moving average price is $10.55.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The firm had revenue of $9.50 million for the quarter, compared to the consensus estimate of $37.26 million. During the same period in the previous year, the business posted ($0.63) earnings per share. The business’s revenue for the quarter was down 84.0% compared to the same quarter last year. On average, sell-side analysts expect that Arvinas, Inc. will post -3.81 EPS for the current year.

Institutional Trading of Arvinas

Several hedge funds and other institutional investors have recently modified their holdings of ARVN. AQR Capital Management LLC acquired a new position in Arvinas during the first quarter valued at $727,000. Jacobs Levy Equity Management Inc. purchased a new position in Arvinas during the 1st quarter valued at about $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after purchasing an additional 2,122 shares during the period. Millennium Management LLC increased its holdings in shares of Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after purchasing an additional 885,483 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Arvinas by 108.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock worth $6,339,000 after purchasing an additional 469,394 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

More Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $20, signaling material upside vs. current levels. Read More.
• Positive Sentiment: Company-level catalysts and financing: coverage highlights Arvinas’ promising PROTAC pipeline and management’s statement that the company has a cash runway into the second half of 2028 — both reduce near‑term financing risk and support longer-term value. Read More.
• Positive Sentiment: Media coverage emphasizing the pipeline helped lift sentiment in futures trading, reinforcing momentum from the Piper Sandler call. Read More.
• Neutral Sentiment: Short-interest reporting is currently anomalous (shows 0 shares / NaN changes) — unclear read on short-selling pressure until corrected data are published.
• Neutral Sentiment: Institutional positioning: several funds (Invesco, Ikarian, others) increased or initiated stakes in Q4, signaling continued institutional interest but concentrated ownership among hedge funds.
• Negative Sentiment: HC Wainwright cut near-term EPS forecasts for Q1–Q4 2026 and lowered FY2026 and FY2027 estimates, reducing near‑term earnings visibility; the firm did raise multi‑year targets (FY2028–FY2030), implying a longer-term recovery but slower near-term performance.
• Negative Sentiment: Q4 results missed badly: Arvinas reported a sizable EPS and revenue shortfall (EPS and revenue well below consensus), the primary fundamental driver weighing on the stock. Read More.
• Negative Sentiment: Insider selling: CEO Randy Teel and CAO David Loomis sold shares on Feb. 23, modestly reducing holdings; such sales can be perceived negatively even if routine. Read More. Read More.

Analysts Set New Price Targets

ARVN has been the subject of several research reports. BTIG Research raised their price objective on shares of Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Barclays lifted their price target on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Stephens increased their price objective on Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Wedbush raised their price objective on Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research report on Monday, December 22nd. Ten investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $13.47.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.